charles_sawyers_beigene_leadership

Charles Sawyers, M.D.

Scientific Advisory Board

Dr. Sawyers is an Investigator for the Howard Hughes Medical Institute, Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis, and Chair of the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center.

A leading researcher in molecularly targeted approaches to treat cancer, Dr. Sawyers has identified cell signaling components critical to the growth of cancer cells in chronic myeloid leukemia, prostate and other cancers. His efforts have led to the development of multiple FDA-approved inhibitors in clinical use today, including imatinib for the treatment of chronic myeloid leukemia and the antiandrogen drug enzalutamide for the treatment of advanced prostate cancer. Dr. Sawyers is a former AACR president and was elected to the 2014 class of Fellows of the AACR Academy. He assumed the Presidency of AACR Academy in 2021.

Dr. Sawyers received a B.A. from Princeton University and an M.D. from Johns Hopkins University School of Medicine.

You are now leaving BeiGene Australia


BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL